Feleke Tilahun Zewdu, Saba Maria Lambert, Michael Marks, Yematawork Kebede Aragaw, Derese Bekele Daba, Kassahun Alemu, Endalamaw Gadisa, Stephen L. Walker
Background
Cutaneous leishmaniasis (CL) is a public health problem in Ethiopia. Diagnosis is often delayed, and treatment options are limited. Liquid nitrogen cryotherapy is a recommended treatment but not widely available. Carbon dioxide (CO2) cryotherapy is used for the prevention of cervical cancer and is widely available in Ethiopia and might be a suitable therapy for treating localized CL.
Objectives
The aim of this short report is to assess the effectiveness of carbon dioxide cryotherapy for the treatment of CL in CL treatment centre, Ethiopia.
Methods
We performed a prospective study assessing the effectiveness of CO2 cryotherapy for the treatment of localized CL between September 2022 and June 2023 at an established CL treatment centre.
Results
Seventeen individuals with 24 CL lesions were enrolled. Twelve (70.6%) were confirmed using a skin slit smear and five by histopathology (29.4%). Nine (52.9%) individuals received a single session of CO2 cryotherapy, five received two (29.4%) and three (17.65%) received three sessions of cryotherapy. At Day 90, 16 participants were assessed and 14 (82.4%) had healed.
Conclusions
CO2 cryotherapy shows promise as a potential treatment strategy for CL. Formal evaluations are required.
{"title":"Effectiveness of Carbon Dioxide Cryotherapy for the Treatment of Localized Cutaneous Leishmaniasis in Ethiopia","authors":"Feleke Tilahun Zewdu, Saba Maria Lambert, Michael Marks, Yematawork Kebede Aragaw, Derese Bekele Daba, Kassahun Alemu, Endalamaw Gadisa, Stephen L. Walker","doi":"10.1002/jvc2.70061","DOIUrl":"https://doi.org/10.1002/jvc2.70061","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cutaneous leishmaniasis (CL) is a public health problem in Ethiopia. Diagnosis is often delayed, and treatment options are limited. Liquid nitrogen cryotherapy is a recommended treatment but not widely available. Carbon dioxide (CO<sub>2</sub>) cryotherapy is used for the prevention of cervical cancer and is widely available in Ethiopia and might be a suitable therapy for treating localized CL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this short report is to assess the effectiveness of carbon dioxide cryotherapy for the treatment of CL in CL treatment centre, Ethiopia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a prospective study assessing the effectiveness of CO<sub>2</sub> cryotherapy for the treatment of localized CL between September 2022 and June 2023 at an established CL treatment centre.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventeen individuals with 24 CL lesions were enrolled. Twelve (70.6%) were confirmed using a skin slit smear and five by histopathology (29.4%). Nine (52.9%) individuals received a single session of CO<sub>2</sub> cryotherapy, five received two (29.4%) and three (17.65%) received three sessions of cryotherapy. At Day 90, 16 participants were assessed and 14 (82.4%) had healed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CO<sub>2</sub> cryotherapy shows promise as a potential treatment strategy for CL. Formal evaluations are required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"830-835"},"PeriodicalIF":0.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ariana Ramírez-Zumbado, Daniel Barquero-Orias, Wendy Vindas-Calderón, Paula Forsythe-Rodríguez
<p>A 22-year-old female patient, known with epilepsy under treatment with chlorpromazine and sodium valproate, with no history of allergies or addictions, presents with a history of 8 months of evolution of a painful, persistent lesion on the sole of the left foot, which had increased in size. Physical examination revealed a deep nodular lesion on the skin of the sole of the left foot with an irregular surface with areas of increased elevation (Figure 1).</p><p>As part of the differential diagnosis, sarcoma versus vascular lesion was initially suggested. Laboratory investigations, blood count, and biochemical profile were performed and reported to be within a normal range. The diagnostic approach began with an imaging study by soft tissue ultrasound, which was reported as possibly a vascular malformation, however, a sarcomatous lesion could be ruled out. Therefore, it was decided to perform an incisional skin biopsy of the lesion.</p><p>The patient was lost for follow-up and could only be re-evaluated 1 year later. Clinically, the lesion persisted and increased in size (Figure 1B). A second skin biopsy and culture for fungi and bacteria were performed (Figure 2).</p><p>Cutaneous botryomycosis is a rare chronic granulomatous infection caused by bacteria. The most frequently implicated germ is <i>S. aureus</i>, however, it can be caused by gram-positive cocci (<i>Streptococci</i> and coagulase-negative <i>Staphylococci</i>), gram-negative bacteria (<i>Pseudomonas aeruginosa</i>, <i>Escherichia coli, Proteus</i> spp, and <i>Serratia</i> spp) and anaerobic bacteria (<i>Peptostreptococci</i> spp and <i>Actinobacilli</i> spp) [<span>1</span>].</p><p>Previous trauma from surgery, burns, disruption of the protective barrier of the skin by microtrauma is often documented. Other identifiable factors are immunocompromise, HIV infection, diabetes mellitus and alcoholism [<span>2, 3</span>]. Botryomycosis can be classified into the cutaneous and the more frequent visceral form. Cutaneous botryomycosis frequently involves exposed parts of the skin, such as the hands, head, and neck or areas of constant trauma such as the feet [<span>2</span>].</p><p>Cutaneous botryomycosis presents characteristically as subcutaneous nodules, ulceration that does not heal with fistulas or verrucous lesions. They are mostly localised lesions, however, deep structures such as bones, muscles, and tendons may be involved by continuity [<span>1, 4</span>]. In addition, any visceral organ [<span>5</span>]. The differential diagnosis of cutaneous botryomycosis includes mycetoma, tuberculosis, actinomycosis, sporotrichosis, and abscesses [<span>6</span>]. The diagnosis is based on culture and histopathology [<span>7</span>]. When botryomycosis is suspected, the bacterial agent must be isolated. Purulent secretions draining from fistulas are useful: Other aetiologic agents can be ruled out using methods such as 10% KOH, polarised light, and different stains such as Ziehl-Neelsen, Fite,
{"title":"Plantar Nodular Lesion in A 22-Year-Old Immunocompetent Female Patient","authors":"Ariana Ramírez-Zumbado, Daniel Barquero-Orias, Wendy Vindas-Calderón, Paula Forsythe-Rodríguez","doi":"10.1002/jvc2.70056","DOIUrl":"https://doi.org/10.1002/jvc2.70056","url":null,"abstract":"<p>A 22-year-old female patient, known with epilepsy under treatment with chlorpromazine and sodium valproate, with no history of allergies or addictions, presents with a history of 8 months of evolution of a painful, persistent lesion on the sole of the left foot, which had increased in size. Physical examination revealed a deep nodular lesion on the skin of the sole of the left foot with an irregular surface with areas of increased elevation (Figure 1).</p><p>As part of the differential diagnosis, sarcoma versus vascular lesion was initially suggested. Laboratory investigations, blood count, and biochemical profile were performed and reported to be within a normal range. The diagnostic approach began with an imaging study by soft tissue ultrasound, which was reported as possibly a vascular malformation, however, a sarcomatous lesion could be ruled out. Therefore, it was decided to perform an incisional skin biopsy of the lesion.</p><p>The patient was lost for follow-up and could only be re-evaluated 1 year later. Clinically, the lesion persisted and increased in size (Figure 1B). A second skin biopsy and culture for fungi and bacteria were performed (Figure 2).</p><p>Cutaneous botryomycosis is a rare chronic granulomatous infection caused by bacteria. The most frequently implicated germ is <i>S. aureus</i>, however, it can be caused by gram-positive cocci (<i>Streptococci</i> and coagulase-negative <i>Staphylococci</i>), gram-negative bacteria (<i>Pseudomonas aeruginosa</i>, <i>Escherichia coli, Proteus</i> spp, and <i>Serratia</i> spp) and anaerobic bacteria (<i>Peptostreptococci</i> spp and <i>Actinobacilli</i> spp) [<span>1</span>].</p><p>Previous trauma from surgery, burns, disruption of the protective barrier of the skin by microtrauma is often documented. Other identifiable factors are immunocompromise, HIV infection, diabetes mellitus and alcoholism [<span>2, 3</span>]. Botryomycosis can be classified into the cutaneous and the more frequent visceral form. Cutaneous botryomycosis frequently involves exposed parts of the skin, such as the hands, head, and neck or areas of constant trauma such as the feet [<span>2</span>].</p><p>Cutaneous botryomycosis presents characteristically as subcutaneous nodules, ulceration that does not heal with fistulas or verrucous lesions. They are mostly localised lesions, however, deep structures such as bones, muscles, and tendons may be involved by continuity [<span>1, 4</span>]. In addition, any visceral organ [<span>5</span>]. The differential diagnosis of cutaneous botryomycosis includes mycetoma, tuberculosis, actinomycosis, sporotrichosis, and abscesses [<span>6</span>]. The diagnosis is based on culture and histopathology [<span>7</span>]. When botryomycosis is suspected, the bacterial agent must be isolated. Purulent secretions draining from fistulas are useful: Other aetiologic agents can be ruled out using methods such as 10% KOH, polarised light, and different stains such as Ziehl-Neelsen, Fite, ","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 5","pages":"1267-1269"},"PeriodicalIF":0.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70056","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145625651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andreas Pinter, Jose Luis López Estebaranz, Anthony Bewley, Jordi Galván, Siva Narayanan, Volker Koscielny, Ismail Kasujee
Background
Effective management of scalp psoriasis needs treatment with high patient preference and treatment satisfaction. Clinical trials show promising results for calcipotriene and betamethasone dipropionate cream based on polyaphron dispersion (PAD) technology (CAL/BDP PAD-cream). However, real-world data are scarce.
Objectives
To evaluate patient- and clinician-reported outcomes and impact of adherence on treatment outcomes of CAL/BDP PAD-cream in adults with mild-to-moderate scalp psoriasis in real-world settings in Europe.
Methods
PRO-SCALP is an ongoing observational, multicentre cohort study, collecting data primarily at baseline and Week 8 (end of the study, EOS). Patient self-assessments included Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9), Scalpdex questionnaire, Worst Itch-Numerical Rating Scale (WI-NRS), sleep patterns, personal preferences and adherence to CAL/BDP PAD-cream using a visual analogue scale (VAS). Clinicians' assessments included physician global assessment of scalp (scalp-PGA) and S-mPASI.
Results
Of 152 patients included in this interim analysis, 134 patients (mean age: 48.4 years; 69.4% females) had evaluable outcome data. At EOS, mean (SD) patient satisfaction scores (TSQM-9) were—effectiveness: 76.0 (23.9), convenience of use: 70.2 (21.3), global satisfaction: 76.1 (22.5). At Week 8, 79.0% of patients attained a scalp-PGA score of 0 (clear) or 1 (almost clear), and 71.0% attained scalp-PGA success, defined as a scalp PGA score of 0/1 and ≥ 2-points improvement in scalp-PGA score change from baseline (CFB). CFB of S-mPASI scores, patient-reported symptoms, emotions, functioning and overall Scalpdex scores as well as WI-NRS scores improved significantly (p < 0.0001) at EOS, within both low-adherence (VAS < 80) and high-adherence (VAS: 80−100) groups. Across key outcome measures, CFB of treatment outcomes was found to be better in patients with higher adherence.
Conclusions
Findings of the study indicate high treatment satisfaction, significant improvement in clinical outcomes and patients' quality of life associated with CAL/BDP PAD-cream, especially in patients with higher adherence.
{"title":"Patient and Clinician-Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD-Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO-SCALP Study","authors":"Andreas Pinter, Jose Luis López Estebaranz, Anthony Bewley, Jordi Galván, Siva Narayanan, Volker Koscielny, Ismail Kasujee","doi":"10.1002/jvc2.70058","DOIUrl":"https://doi.org/10.1002/jvc2.70058","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Effective management of scalp psoriasis needs treatment with high patient preference and treatment satisfaction. Clinical trials show promising results for calcipotriene and betamethasone dipropionate cream based on polyaphron dispersion (PAD) technology (CAL/BDP PAD-cream). However, real-world data are scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate patient- and clinician-reported outcomes and impact of adherence on treatment outcomes of CAL/BDP PAD-cream in adults with mild-to-moderate scalp psoriasis in real-world settings in Europe.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PRO-SCALP is an ongoing observational, multicentre cohort study, collecting data primarily at baseline and Week 8 (end of the study, EOS). Patient self-assessments included Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9), Scalpdex questionnaire, Worst Itch-Numerical Rating Scale (WI-NRS), sleep patterns, personal preferences and adherence to CAL/BDP PAD-cream using a visual analogue scale (VAS). Clinicians' assessments included physician global assessment of scalp (scalp-PGA) and S-mPASI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 152 patients included in this interim analysis, 134 patients (mean age: 48.4 years; 69.4% females) had evaluable outcome data. At EOS, mean (SD) patient satisfaction scores (TSQM-9) were—effectiveness: 76.0 (23.9), convenience of use: 70.2 (21.3), global satisfaction: 76.1 (22.5). At Week 8, 79.0% of patients attained a scalp-PGA score of 0 (clear) or 1 (almost clear), and 71.0% attained scalp-PGA success, defined as a scalp PGA score of 0/1 and ≥ 2-points improvement in scalp-PGA score change from baseline (CFB). CFB of S-mPASI scores, patient-reported symptoms, emotions, functioning and overall Scalpdex scores as well as WI-NRS scores improved significantly (<i>p</i> < 0.0001) at EOS, within both low-adherence (VAS < 80) and high-adherence (VAS: 80−100) groups. Across key outcome measures, CFB of treatment outcomes was found to be better in patients with higher adherence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Findings of the study indicate high treatment satisfaction, significant improvement in clinical outcomes and patients' quality of life associated with CAL/BDP PAD-cream, especially in patients with higher adherence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"791-802"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ji Fung Yong, Michael O'Connell, Alana Durack, Lyndsey Paul
Background
Synchronous melanoma (SM) is defined as ≥ 2 melanomas diagnosed at the same time, or within 3 months of diagnosing the first melanoma, and occurs rarely.
Objectives
The objective of this study was to review all the cases of SM discussed at the melanoma MDT meeting in our cancer centre over the last 5 years.
Methods
Melanoma MDT lists, histopathology and clinical records were reviewed from July 2018 to July 2023 inclusive, for new SMs. This study includes invasive malignant melanoma (MM), lentigo maligna (LM) and melanoma in situ (MIS).
Results
1082 patients were diagnosed with cutaneous melanomas over the 5-year period. Of these patients, 33 patients (3.05%) with SMs were identified in 21 males and 12 females. Ages ranged from 44 to 93 years. Twenty-four patients (72.7%) had SMs diagnosed at the same time and nine (27.3%) had subsequent melanoma diagnosed within a 3-month period. Risk factors noted included family history of melanoma (6.06%, n = 2), history of immunosuppression (12.1%, n = 4), and history of previous non-melanoma skin cancer (6.06%, n = 2). Of the total number of SMs (n = 68), 26.5% (n = 18) were invasive, 20.6% (n = 14) were LMs and 52.9% (n = 36) were MIS. Most lesions (33.9%, n = 21) were located on the trunk, with 13 (62%) on the back. Sixteen (48.5%) patients had both synchronous in situ lesions, 16 patients had LM/MIS with an invasive melanoma (pathological stage 1a to 4b) and 1 (2.4%) patient had stage 1a with stage 1b melanoma.
Conclusions
To the best of our knowledge, this is the largest retrospective study to date of SM. It highlights the importance of a full skin check especially once a melanoma has been identified, to ensure further melanomas are not missed.
{"title":"Synchronous Melanoma: A Single-Centre 5-Year Retrospective Study","authors":"Ji Fung Yong, Michael O'Connell, Alana Durack, Lyndsey Paul","doi":"10.1002/jvc2.70064","DOIUrl":"https://doi.org/10.1002/jvc2.70064","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Synchronous melanoma (SM) is defined as ≥ 2 melanomas diagnosed at the same time, or within 3 months of diagnosing the first melanoma, and occurs rarely.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this study was to review all the cases of SM discussed at the melanoma MDT meeting in our cancer centre over the last 5 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Melanoma MDT lists, histopathology and clinical records were reviewed from July 2018 to July 2023 inclusive, for new SMs. This study includes invasive malignant melanoma (MM), lentigo maligna (LM) and melanoma in situ (MIS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>1082 patients were diagnosed with cutaneous melanomas over the 5-year period. Of these patients, 33 patients (3.05%) with SMs were identified in 21 males and 12 females. Ages ranged from 44 to 93 years. Twenty-four patients (72.7%) had SMs diagnosed at the same time and nine (27.3%) had subsequent melanoma diagnosed within a 3-month period. Risk factors noted included family history of melanoma (6.06%, <i>n</i> = 2), history of immunosuppression (12.1%, <i>n</i> = 4), and history of previous non-melanoma skin cancer (6.06%, <i>n</i> = 2). Of the total number of SMs (<i>n</i> = 68), 26.5% (<i>n</i> = 18) were invasive, 20.6% (<i>n</i> = 14) were LMs and 52.9% (<i>n</i> = 36) were MIS. Most lesions (33.9%, <i>n</i> = 21) were located on the trunk, with 13 (62%) on the back. Sixteen (48.5%) patients had both synchronous in situ lesions, 16 patients had LM/MIS with an invasive melanoma (pathological stage 1a to 4b) and 1 (2.4%) patient had stage 1a with stage 1b melanoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>To the best of our knowledge, this is the largest retrospective study to date of SM. It highlights the importance of a full skin check especially once a melanoma has been identified, to ensure further melanomas are not missed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"840-844"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mariana de la Vega, María Antonieta Domínguez Gómez, Martha Alejandra Morales-Sánchez
Background
Mycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma, and less than 5% of cases occur in paediatric patients. No treatment standardized guidelines exist for paediatric population, and evidence comes from small retrospective studies. No studies in Mexican children were identified.
Objectives
To describe epidemiological data, to determine treatment response and factors associated with remission or relapse, and to examine the impact of diagnosis delay in complete remission.
Methods
We retrospectively analysed records of all patients aged 0−18 years diagnosed with MF who were treated in Centro Dermatológico Pascua, between January 2007 and July 2023.
Results
One hundred and twenty-three patients were included. The median age at diagnosis was 12 years. All patients presented with early clinical stages (IA/IB). Hypopigmented phenotype was present in 70.7%. Phototherapy was the most frequently indicated treatment (89.4%). Complete remission was achieved by 35.8% in a median of 16.54 ± 14.74 months. Involved body surface area (BSA), duration of disease and phototherapy were inversely associated with complete remission. The median time to follow-up was 19 months (range 40 months), with an overall survival of 100%, and no disease progression. Relapse was present in 15.44%, and associated predictors were skin phototype and clinical variants different from hypopigmented. BSA and the duration of the disease were negatively associated. Institutional diagnosis delay had a median of 3 months (range 0.8−10.7 months), with no statistically significant impact in complete remission.
Conclusions
To our knowledge, this study represents the largest paediatric cohort worldwide, and the first to examine the Mexican population. Phototherapy is the most prescribed treatment modality in our centre, with acceptable remission rates. Our study confirms a favourable prognosis of MF in children. Prospective studies are needed to better characterize the epidemiology and clinical course of the disease, to determine treatment efficacy and to identify prognostic factors.
{"title":"Mycosis Fungoides in Paediatric Patients: A Real-Life Retrospective Study","authors":"Mariana de la Vega, María Antonieta Domínguez Gómez, Martha Alejandra Morales-Sánchez","doi":"10.1002/jvc2.70059","DOIUrl":"https://doi.org/10.1002/jvc2.70059","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma, and less than 5% of cases occur in paediatric patients. No treatment standardized guidelines exist for paediatric population, and evidence comes from small retrospective studies. No studies in Mexican children were identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To describe epidemiological data, to determine treatment response and factors associated with remission or relapse, and to examine the impact of diagnosis delay in complete remission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analysed records of all patients aged 0−18 years diagnosed with MF who were treated in Centro Dermatológico Pascua, between January 2007 and July 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and twenty-three patients were included. The median age at diagnosis was 12 years. All patients presented with early clinical stages (IA/IB). Hypopigmented phenotype was present in 70.7%. Phototherapy was the most frequently indicated treatment (89.4%). Complete remission was achieved by 35.8% in a median of 16.54 ± 14.74 months. Involved body surface area (BSA), duration of disease and phototherapy were inversely associated with complete remission. The median time to follow-up was 19 months (range 40 months), with an overall survival of 100%, and no disease progression. Relapse was present in 15.44%, and associated predictors were skin phototype and clinical variants different from hypopigmented. BSA and the duration of the disease were negatively associated. Institutional diagnosis delay had a median of 3 months (range 0.8−10.7 months), with no statistically significant impact in complete remission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>To our knowledge, this study represents the largest paediatric cohort worldwide, and the first to examine the Mexican population. Phototherapy is the most prescribed treatment modality in our centre, with acceptable remission rates. Our study confirms a favourable prognosis of MF in children. Prospective studies are needed to better characterize the epidemiology and clinical course of the disease, to determine treatment efficacy and to identify prognostic factors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"783-790"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer Cather, Melodie Young, Muriel Boreham, Shehla Admani, Tina Bhutani, Erin Foster, Richard Fried, Melinda Gooderham, Jeannette Jakus, Sandra Johnson, Ryoichi Kamide, John Koo, Tiffany Mayo, Michael Payette, Caitriona Ryan, Lucinda Whitney, Krista Bohnert, Melissa Seal, Patrick Burnett, Diane Hanna
Background
Psoriasis occurring on the skin of the genital and perigenital regions, including the inguinal creases, vulva, penis, scrotum, perianal area, and the intergluteal cleft, has specific diagnostic and treatment requirements due to the sensitivity and private nature of these areas.
Objectives
A multidisciplinary group of 13 US-based clinicians who are experts in the management of genital psoriasis, the Genital Psoriasis Wellness Consortium, convened to discuss the impact of genital psoriasis on patients focusing on three main domains: (1) physical diagnosis and patient conversations, (2) impact on patient quality of life/interpersonal relationships, and (3) treatment decisions.
Methods
A PubMed literature search was conducted, and the Consortium members used the results to formulate their consensus statements using a modified Delphi process, including a nominal group technique. The process included two rounds of virtual subcommittee meetings based on the three domains, followed by surveys to obtain anonymous feedback, and concluded with a final meeting to discuss and finalize the language of the consensus recommendations across all three domains. Three additional psoriasis experts provided feedback on these consensus statements from Canadian, European, and Asian perspectives.
Results
Herein, we report our 14 consensus statements and a summary of the supporting data.
Conclusions
These consensus statements are meant as a practical resource for clinicians to ensure that symptoms of genital psoriasis are not overlooked. We hope to continue to add to these statements as additional clinical data become available.
{"title":"Genital Psoriasis: Shining Light on This Hidden Disease","authors":"Jennifer Cather, Melodie Young, Muriel Boreham, Shehla Admani, Tina Bhutani, Erin Foster, Richard Fried, Melinda Gooderham, Jeannette Jakus, Sandra Johnson, Ryoichi Kamide, John Koo, Tiffany Mayo, Michael Payette, Caitriona Ryan, Lucinda Whitney, Krista Bohnert, Melissa Seal, Patrick Burnett, Diane Hanna","doi":"10.1002/jvc2.70043","DOIUrl":"https://doi.org/10.1002/jvc2.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis occurring on the skin of the genital and perigenital regions, including the inguinal creases, vulva, penis, scrotum, perianal area, and the intergluteal cleft, has specific diagnostic and treatment requirements due to the sensitivity and private nature of these areas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>A multidisciplinary group of 13 US-based clinicians who are experts in the management of genital psoriasis, the Genital Psoriasis Wellness Consortium, convened to discuss the impact of genital psoriasis on patients focusing on three main domains: (1) physical diagnosis and patient conversations, (2) impact on patient quality of life/interpersonal relationships, and (3) treatment decisions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A PubMed literature search was conducted, and the Consortium members used the results to formulate their consensus statements using a modified Delphi process, including a nominal group technique. The process included two rounds of virtual subcommittee meetings based on the three domains, followed by surveys to obtain anonymous feedback, and concluded with a final meeting to discuss and finalize the language of the consensus recommendations across all three domains. Three additional psoriasis experts provided feedback on these consensus statements from Canadian, European, and Asian perspectives.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Herein, we report our 14 consensus statements and a summary of the supporting data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These consensus statements are meant as a practical resource for clinicians to ensure that symptoms of genital psoriasis are not overlooked. We hope to continue to add to these statements as additional clinical data become available.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"719-731"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nana A. Adjei-Frimpong, Julian Cortes, Savannah K. Fakhouri, Francesco Delacqua, Reid Oldenburg
Background
Chronic urticaria (CU) is characterised by recurring itchy hives lasting more than 6 weeks, with or without angioedema. Although CU patients are known to have an increased likelihood of psychiatric comorbidities, research exploring this connection in diverse populations remains limited.
Objectives
This study investigates the association between CU and psychiatric disorders using the All of Us (AoU) database, a nationwide initiative designed to enhance research in underrepresented populations.
Methods
We conducted a nested case-control study among US adults in the AoU program from May 6, 2018 to February 26, 2025. SNOMED codes were used to identify CU cases that were then matched 4:1 to controls by age, sex, ethnicity, and smoking status. Psychiatric comorbidities were assessed using logistic regression models adjusted for hypothyroidism, systemic lupus erythematosus, and rheumatoid arthritis.
Results
We identified 1171 CU cases and 4684 matched controls. CU was significantly associated with increased odds of ADHD (odds ratio [OR], 3.61; 95% confidence interval [CI], 2.62–4.96), anxiety (OR, 3.48; 95% CI, 3.03–3.99), depression (OR, 3.26; 95% CI, 2.84–3.75), dysthymia (OR, 3.67; 95% CI, 2.89–4.66), insomnia (OR, 3.27; 95% CI, 2.77–3.86), psychological stress (OR, 3.92; 95% CI, 3.09–4.96), PTSD (OR, 3.25; 95% CI, 2.53–4.17), and substance use disorder (OR, 2.13; 95% CI, 1.74–2.62).
Conclusions
These findings highlight the psychiatric burden associated with CU and demonstrates the importance of routine psychiatric screenings for CU patients to allow early intervention. Prospective studies investigating additional psychiatric disorders and underlying mechanisms will help clarify meaningful associations and guide appropriate psychiatric screening and management.
{"title":"Association of Psychiatric Comorbidities With Chronic Urticaria: A Nested Case-Control Study in the All of Us Research Program","authors":"Nana A. Adjei-Frimpong, Julian Cortes, Savannah K. Fakhouri, Francesco Delacqua, Reid Oldenburg","doi":"10.1002/jvc2.70063","DOIUrl":"https://doi.org/10.1002/jvc2.70063","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic urticaria (CU) is characterised by recurring itchy hives lasting more than 6 weeks, with or without angioedema. Although CU patients are known to have an increased likelihood of psychiatric comorbidities, research exploring this connection in diverse populations remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study investigates the association between CU and psychiatric disorders using the All of Us (AoU) database, a nationwide initiative designed to enhance research in underrepresented populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a nested case-control study among US adults in the AoU program from May 6, 2018 to February 26, 2025. SNOMED codes were used to identify CU cases that were then matched 4:1 to controls by age, sex, ethnicity, and smoking status. Psychiatric comorbidities were assessed using logistic regression models adjusted for hypothyroidism, systemic lupus erythematosus, and rheumatoid arthritis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 1171 CU cases and 4684 matched controls. CU was significantly associated with increased odds of ADHD (odds ratio [OR], 3.61; 95% confidence interval [CI], 2.62–4.96), anxiety (OR, 3.48; 95% CI, 3.03–3.99), depression (OR, 3.26; 95% CI, 2.84–3.75), dysthymia (OR, 3.67; 95% CI, 2.89–4.66), insomnia (OR, 3.27; 95% CI, 2.77–3.86), psychological stress (OR, 3.92; 95% CI, 3.09–4.96), PTSD (OR, 3.25; 95% CI, 2.53–4.17), and substance use disorder (OR, 2.13; 95% CI, 1.74–2.62).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings highlight the psychiatric burden associated with CU and demonstrates the importance of routine psychiatric screenings for CU patients to allow early intervention. Prospective studies investigating additional psychiatric disorders and underlying mechanisms will help clarify meaningful associations and guide appropriate psychiatric screening and management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"836-839"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael J. Diaz, Zaim Haq, Jasmine T. Tran, Parsa Abdi, Nicole Natarelli, Wilson Liao, Marjorie E. Montanez-Wiscovich
Background
Higher prevalence of sleep disorders is seen in persons with psoriasis (PsO). However, the extent to which sleep conditions are linked to PsO severity, particularly across diverse populations, remains unknown. Bridging this knowledge gap is vital for developing comprehensive, equitable and personalized care strategies.
Objectives
We aimed to quantify the extent to which psoriasis severity correlates with the risk of developing specific sleep disorders, and to identify how these associations vary by racial/ethnic group, using robust covariate adjustments.
Methods
Health records for 7743 adults with psoriasis were obtained from the All of Us sample—an NIH database initiative that oversamples underrepresented populations. Cases were selectively matched 1:4 to age-, sex-, and race/ethnicity-matched controls, and differences were interrogated by multivariable regression.
Results
Mild PsO was significantly associated with restless leg syndrome, insomnia and obstructive sleep apnoea after adjusting for sociodemographic variables and comorbidities. Moderate-to-severe PsO demonstrated greater magnitudes of association. We additionally observed a magnified sleep disorder risk in non-White patients, particularly for insomnia and OSA.
Conclusions
Both mild and moderate-to-severe psoriasis is significantly associated with an increased risk of sleep disorders, with notable variations across different racial/ethnic groups.
{"title":"The Association of Psoriasis With Sleep Disorders in a Diverse National Cohort","authors":"Michael J. Diaz, Zaim Haq, Jasmine T. Tran, Parsa Abdi, Nicole Natarelli, Wilson Liao, Marjorie E. Montanez-Wiscovich","doi":"10.1002/jvc2.70022","DOIUrl":"https://doi.org/10.1002/jvc2.70022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Higher prevalence of sleep disorders is seen in persons with psoriasis (PsO). However, the extent to which sleep conditions are linked to PsO severity, particularly across diverse populations, remains unknown. Bridging this knowledge gap is vital for developing comprehensive, equitable and personalized care strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We aimed to quantify the extent to which psoriasis severity correlates with the risk of developing specific sleep disorders, and to identify how these associations vary by racial/ethnic group, using robust covariate adjustments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Health records for 7743 adults with psoriasis were obtained from the All of Us sample—an NIH database initiative that oversamples underrepresented populations. Cases were selectively matched 1:4 to age-, sex-, and race/ethnicity-matched controls, and differences were interrogated by multivariable regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mild PsO was significantly associated with restless leg syndrome, insomnia and obstructive sleep apnoea after adjusting for sociodemographic variables and comorbidities. Moderate-to-severe PsO demonstrated greater magnitudes of association. We additionally observed a magnified sleep disorder risk in non-White patients, particularly for insomnia and OSA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Both mild and moderate-to-severe psoriasis is significantly associated with an increased risk of sleep disorders, with notable variations across different racial/ethnic groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"821-825"},"PeriodicalIF":0.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lea Schulte-Oestrich, Simone Cazzaniga, Robert E. Hunger, S. Morteza Seyed Jafari
Background
Despite the existence of therapeutic approaches, effective management of hidradenitis suppurativa (HS) remains elusive in many cases. In addition, most of the current studies focus on treatment response in a cross-sectional analysis of patients, and therefore a proper study analysing different treatment strategies longitudinally in each individual patient is still lacking.
Objectives
The current study aimed to provide insight into HS patients treated with different treatment strategies and to clarify the reasons for switching or discontinuing each treatment group.
Methods
The single-center, retrospective study collected information on patient characteristics and management strategies, focusing on different treatment groups and reasons for discontinuation or switching.
Results
Ninety-eight patients were included in the study (53.1% males, median age 38.5 years). During the study period, 98.0% of patients had at least one prescription of topical therapy, particularly non-antibiotics disinfectants. 92.9% of patients also received a prescription for systemic antibiotics, especially tetracyclines (86.7%). 26.5% were prescribed biologic therapies, mainly TNF-alpha blockers (25.5%), with a median time to start treatment of 0.9 years. Non-biologic systemic therapies (relative risk [RR]: 1.54; 95% confidence interval [CI] 1.28–1.85) and systemic antibiotics (RR: 1.97; 95% CI: 1.56–2.48) showed a moderate-to-high risk of discontinuation. The most frequent switching patterns were from topicals plus systemic antibiotics to the same combination plus other therapies (11.2%), including surgery and laser, to topical treatment alone (8.5%), or to topicals plus biologics (4.5%).
Conclusions
Standard care management of HS requires a personalized, multifaceted approach, typically involving a combination of local and systemic treatments, with antibiotics often used first. When antibiotics and other systemic agents are ineffective, biologics may be used alone or with antibiotics; delaying their use can miss the chance to prevent disease progression and the possible ‘window of opportunity’ in the treatment of HS.
{"title":"Treatment Survival in Patients With Hidradenitis Suppurativa","authors":"Lea Schulte-Oestrich, Simone Cazzaniga, Robert E. Hunger, S. Morteza Seyed Jafari","doi":"10.1002/jvc2.70027","DOIUrl":"https://doi.org/10.1002/jvc2.70027","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite the existence of therapeutic approaches, effective management of hidradenitis suppurativa (HS) remains elusive in many cases. In addition, most of the current studies focus on treatment response in a cross-sectional analysis of patients, and therefore a proper study analysing different treatment strategies longitudinally in each individual patient is still lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The current study aimed to provide insight into HS patients treated with different treatment strategies and to clarify the reasons for switching or discontinuing each treatment group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The single-center, retrospective study collected information on patient characteristics and management strategies, focusing on different treatment groups and reasons for discontinuation or switching.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-eight patients were included in the study (53.1% males, median age 38.5 years). During the study period, 98.0% of patients had at least one prescription of topical therapy, particularly non-antibiotics disinfectants. 92.9% of patients also received a prescription for systemic antibiotics, especially tetracyclines (86.7%). 26.5% were prescribed biologic therapies, mainly TNF-alpha blockers (25.5%), with a median time to start treatment of 0.9 years. Non-biologic systemic therapies (relative risk [RR]: 1.54; 95% confidence interval [CI] 1.28–1.85) and systemic antibiotics (RR: 1.97; 95% CI: 1.56–2.48) showed a moderate-to-high risk of discontinuation. The most frequent switching patterns were from topicals plus systemic antibiotics to the same combination plus other therapies (11.2%), including surgery and laser, to topical treatment alone (8.5%), or to topicals plus biologics (4.5%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Standard care management of HS requires a personalized, multifaceted approach, typically involving a combination of local and systemic treatments, with antibiotics often used first. When antibiotics and other systemic agents are ineffective, biologics may be used alone or with antibiotics; delaying their use can miss the chance to prevent disease progression and the possible ‘window of opportunity’ in the treatment of HS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"751-758"},"PeriodicalIF":0.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christina Asare, Jennifer Chen, Pragna Naidoo, Caroline Raymundo, Marianne Tawa, Nilufer Khan, Elise Olsen, Rosanne Ottevanger, Julia Scarisbrick, Susan Thornton, Ellen J. Kim, Cecilia Larocca, Michi M. Shinohara, International Dermatology Outcomes Measures (IDEOM) CTCL Workgroup
Background
There is no consensus on how best to assess the impact of living with mycosis fungoides (MF)/Sézary syndrome (SS) on a patient's quality of life.
Objectives
To identify all potential concepts that describe disease severity or contribute to health-related quality of life (HRQOL) from patients with MF/SS and their care partners.
Methods
A systemic literature review of articles and meeting abstracts published between 2000 and 2022 was conducted. Inclusion criteria were any study that included MF/SS patients or care partners and reported any concept that patients or care partners could use to characterize any aspect of MF/SS. Thematic analysis was completed using NVIVO.
Results
One hundred and three articles/abstracts met inclusion criteria. Within these studies, 30 existing instruments were utilized. Concepts within these existing instruments fell into the following health component categories: Physical-functional well-being (PF; 50.4%), mental health/emotional well-being (MHE; 26.6%), social well-being (S; 18.3%) or other (O; 4.7%). The most frequently measured concepts by existing instruments were physical mobility (7.5%), itching (7.2%), pain (7.0%) and fatigue (5.2%). One study conducted content validity analysis for an included instrument. Distinct concepts were identified from qualitative studies and novel instruments, and included hair loss, nail changes, cracking/fissuring of the skin, inability to regulate temperature, difficulty with wound dressings, skin infection, skin oozing/weeping/bleeding, pigmentary changes, treatment burden and treatment satisfaction, and care partners' specific concepts. One study conducted content validity analysis for an included instrument.
Conclusions
Numerous PROMs have been used to assess HRQOL for patients with MF/SS, with very little content validity analysis. Several concepts identified from qualitative studies and newly developed or piloted instruments are not represented in existing PROMs. Future efforts will include prioritizing candidate core concepts by stakeholders to develop a core domain set that captures the most relevant aspects of MF/SS that impact HRQOL.
{"title":"Defining Core Concepts for Health-Related Quality of Life for Patients With Mycosis Fungoides and Sézary Syndrome: A Systematic Literature Review","authors":"Christina Asare, Jennifer Chen, Pragna Naidoo, Caroline Raymundo, Marianne Tawa, Nilufer Khan, Elise Olsen, Rosanne Ottevanger, Julia Scarisbrick, Susan Thornton, Ellen J. Kim, Cecilia Larocca, Michi M. Shinohara, International Dermatology Outcomes Measures (IDEOM) CTCL Workgroup","doi":"10.1002/jvc2.70039","DOIUrl":"https://doi.org/10.1002/jvc2.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is no consensus on how best to assess the impact of living with mycosis fungoides (MF)/Sézary syndrome (SS) on a patient's quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To identify all potential concepts that describe disease severity or contribute to health-related quality of life (HRQOL) from patients with MF/SS and their care partners.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systemic literature review of articles and meeting abstracts published between 2000 and 2022 was conducted. Inclusion criteria were any study that included MF/SS patients or care partners and reported any concept that patients or care partners could use to characterize any aspect of MF/SS. Thematic analysis was completed using NVIVO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and three articles/abstracts met inclusion criteria. Within these studies, 30 existing instruments were utilized. Concepts within these existing instruments fell into the following health component categories: Physical-functional well-being (PF; 50.4%), mental health/emotional well-being (MHE; 26.6%), social well-being (S; 18.3%) or other (O; 4.7%). The most frequently measured concepts by existing instruments were physical mobility (7.5%), itching (7.2%), pain (7.0%) and fatigue (5.2%). One study conducted content validity analysis for an included instrument. Distinct concepts were identified from qualitative studies and novel instruments, and included hair loss, nail changes, cracking/fissuring of the skin, inability to regulate temperature, difficulty with wound dressings, skin infection, skin oozing/weeping/bleeding, pigmentary changes, treatment burden and treatment satisfaction, and care partners' specific concepts. One study conducted content validity analysis for an included instrument.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Numerous PROMs have been used to assess HRQOL for patients with MF/SS, with very little content validity analysis. Several concepts identified from qualitative studies and newly developed or piloted instruments are not represented in existing PROMs. Future efforts will include prioritizing candidate core concepts by stakeholders to develop a core domain set that captures the most relevant aspects of MF/SS that impact HRQOL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"907-919"},"PeriodicalIF":0.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号